永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 12-19 16:08:47

2.380

+0.100

+4.39%

最高2.520	最低2.080	成交量96.50万
今开2.180	昨收2.280	日振幅19.30%
总市值12.25亿	流通市值12.25亿	总股本5.15亿
成交额222.88万	换手率0.19%	流通股本5.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.38,"timestamp":1734595727020,"preClose":2.28,"halted":0,"volume":965000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.6979752,"marketStatus":"已收盘","marketStatusCode":5,"change":0.1,"latestTime":"12-19 16:08:47","open":2.18,"high":2.52,"low":2.08,"amount":2228820,"amplitude":0.192982,"askPrice":2.39,"askSize":2000,"bidPrice":2.37,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.6446106129609182,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1594310400000,"adjPreClose":2.28,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":1.193126,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/tweets","defaultTab":"tweets","newsList":[{"id":"2492145201","title":"中生制药(01177.HK)将为创新药递交ASPS适应症上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2492145201","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492145201?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:39","pubTimestamp":1734597540,"startTime":"0","endTime":"0","summary":"中生制药公布，集团自主研发的1类创新药贝莫苏拜单抗注射液联合盐酸安罗替尼胶囊，已向中国药监局药品审评中心就新增晚期腺泡状软组织肉瘤适应症的上市申请进行沟通，并获得CDE书面同意提交上市申请。集团将于近期递交上市申请。ASPS是安罗替尼即将申报上市的第12个适应症、贝莫苏拜单抗即将申报上市的第5个适应症，有望为ASPS患者带来新的治疗选择。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405300&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06978","BK1589","01477","01177","BK1161","BK1515","BK1191","159992","BK1521"],"gpt_icon":0},{"id":"2492611718","title":"永泰生物－Ｂ(06978)股价下跌5.263%，现价港币$2.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2492611718","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492611718?lang=zh_cn&edition=full","pubTime":"2024-12-19 15:10","pubTimestamp":1734592200,"startTime":"0","endTime":"0","summary":"[下跌股]永泰生物－Ｂ(06978) 股价在下午03:10比前收市价下跌5.263%，现股价为港币$2.16。至目前为止，今日最高价为$2.52，而最低价为$2.12。总成交量为71.9万股，总成交金额为港币$169.24万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2412192088/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2492030115","title":"港股异动 | 永泰生物-B(06978)午后涨超9% CAR-T-19注射液获授予突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2492030115","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492030115?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:48","pubTimestamp":1734587289,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，永泰生物-B午后涨超9%，截至发稿，涨9.65%，报2.5港元，成交额66.03万港元。消息面上，永泰生物近期公布，集团的产品CAR-T–19注射液获得国家药品监督管理局药品审评中心颁发的突破性疗法认定，用于治疗25岁及以下复发╱难治B细胞急性淋巴细胞白血病患者。该认定乃基于CAR-T–19注射液可靠的临床疗效及安全性数据。其将加快CAR-T–19注射液的临床开发，并加速其早日与患者见面。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4022","BK1574","06978","CAR","BK4230"],"gpt_icon":0},{"id":"2492196464","title":"年终盘点 | 投融资环境好转：医药业有望走出低谷，创新药企或批量扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2492196464","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492196464?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:19","pubTimestamp":1734574744,"startTime":"0","endTime":"0","summary":"2024年宏观经济下行压力加深，支付端控费压力显著增大，医疗反腐力度未见放缓等因素叠加下，医药生物行业明显承压。不过，今年我国推出了一系列支持创新药发展的政策，旨在激励国内创新药研发和加速新药上市。生物制造行业中，创新药研发是新质生产力的最重要体现之一。有多家药企向蓝鲸财经表示，近期我国医药投融资环境有所好转，不少企业经过数年打磨，已经能够看到盈利的希望，医药行业正在逐步走出底部。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/247285","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2492198367","title":"永泰生物-B盘中异动 早盘股价大跌7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492198367","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492198367?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:34","pubTimestamp":1734572046,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘09时34分，永泰生物-B股票出现异动，股价急速下挫7.02%。截至发稿，该股报2.120港元/股，成交量8000股，换手率0.00%，振幅2.63%。资金方面，该股资金流入2120港元，流出2180港元。永泰生物-B股票所在的生物技术行业中，整体跌幅为0.66%。永泰生物-B公司简介：永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093406984cbfc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093406984cbfc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2492891167","title":"【券商聚焦】交银国际预计2025年商保将有望进一步发展 协助解决创新药支付问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2492891167","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492891167?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:59","pubTimestamp":1734569982,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际预计2025年商保将有望进一步发展，协助解决创新药支付问题。同时，丙类目录+商保差异化发展的创新支付机制或缓解创新药械企业面临的进院难、报销支付难问题。近期医药板块在大幅震荡后有所回落，考虑到板块估值仍处于历史底部、叠加后续财政、医保/商保利好政策出台+流动性改善，该行认为仍有进一步修复空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK1589","LU0417516571.SGD","LU1720050803.USD","IE00B543WZ88.USD","09926","01177","BK1515","BK1521","159992","02096","06978","01952","BK1583","LU1794554557.SGD","BK1191","LU0348783233.USD","BK1147","LU0348784397.USD","BK1161","03329","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2492901547","title":"中国生物制药创新药III期研究取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2492901547","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492901547?lang=zh_cn&edition=full","pubTime":"2024-12-18 19:01","pubTimestamp":1734519698,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩）12月18日，中国生物制药发布公告称，其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412183272216750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272216750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","06978","BK1191","01177","BK1574","BK1589","III","BK1161","BK4134","BK1521"],"gpt_icon":0},{"id":"2492932908","title":"【港股通】上海医药(02607)拟用于治疗精神分裂症的创新药“I048”临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932908","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492932908?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:32","pubTimestamp":1734514347,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上海医药(02607)，集团开发的“I048”临床试验申请收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。I048是小分子一类新药，拟用于治疗精神分裂症。临床前研究显示在动物疾病模型上起到显著的治疗作用。该项目由上海医药集团股份有限公司主导研发，公司拥有全球独占实施许可权益。截至目前，该项目已累计投入研发费用为2,516.30万元人民币。截至本公告日，全球未有完全相同靶点和同适应症的药品上市。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK1576","159992","BK0209","BK0012","03347","BK0028","02607","BK0097","BK1141","HSCEI","BK0188","BK0184","BK0175","BK1583","BK0099","HSTECH","BK1197","06978","YANG","BK1161","BK0183","BK1574","601607","BK0187","BK0020"],"gpt_icon":0},{"id":"2492597703","title":"中国生物制药创新药研究获阳性结果 申请上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2492597703","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492597703?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:23","pubTimestamp":1734513797,"startTime":"0","endTime":"0","summary":"财中社12月18日电中国生物制药（01177）发布公告，宣布其自主研发的1类创新药贝莫苏拜单抗注射液联合或不联合盐酸安罗替尼胶囊在非小细胞肺癌（NSCLC）放化疗后巩固治疗的III期研究取得阳性结果。该研究的期中分析显示，贝莫苏拜单抗的联合治疗显著延长了患者的无进展生存期（PFS），并降低了疾病进展或死亡风险。独立数据监查委员会已判定主要研究终点达到预设的优效界值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272169369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","01177","BK1521","BK1161","BK1515","06978","BK1191","BK1574"],"gpt_icon":0},{"id":"2492764977","title":"上市后亏损超27亿，这家创新药企拟赴港二次上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2492764977","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492764977?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:22","pubTimestamp":1734513720,"startTime":"0","endTime":"0","summary":"　　12月16日-18日，迈威生物三个交易日合计下跌8.33%。　　从2024年年初以来，多家上市公司掀起“A赴H”热潮。近日，迈威生物宣布计划发行H股股票并在香港联交所上市。截至今年三季度末，迈威生物存在净利亏损、资产负债率攀升、货币资金储备缩水等情形。经计算，迈威生物上市后合计亏损金额超27亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-12-18/doc-inczwpwp8060658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2492192671","title":"首只份额破百亿的港股创新药主题ETF诞生","url":"https://stock-news.laohu8.com/highlight/detail?id=2492192671","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492192671?lang=zh_cn&edition=full","pubTime":"2024-12-18 12:57","pubTimestamp":1734497845,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["US12M.BOND",".SPX","UPRO","TNmain","BK4550","IVV","OEX","SPY","SSO","BK4585","BK1574","HSCEI","HK0000934320.USD","HSTECH","BK1161","ZFmain","ESmain","UBmain","US2Y.BOND","US6M.BOND","SDS","YANG","BK4534","BK4581","US30Y.BOND","FDN","SPXU","US7Y.BOND","07226","06978","ZBmain","513120","BK4504","ZNmain","OEF","BK4559","SH","159992","US10Y.BOND","ZTmain","US3Y.BOND","US5Y.BOND","BK4588"],"gpt_icon":0},{"id":"2492941582","title":"创新药概念多数上扬 圣诺医药(02257)涨11.56% 机构指医药创新是医药增长的核心动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2492941582","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492941582?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:55","pubTimestamp":1734486946,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念多数上扬，圣诺医药 涨11.56%，百奥赛图涨9.68%，歌礼制药涨7.98%，绿竹生物涨4.73%，再鼎医药涨4.41%，康诺亚涨1.34%，中国生物制药涨0.95%，信达生物涨0.69%银河证券表示，1）医药创新是医药增长的核心动力。对于医药板块， 在“医保+商保”模式不断推进、政策支持等因素驱动下，行业规模有望进一步扩大。“医保+商保”模式打开健康险空间，创新药发展空间更大。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949850","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","159992","01672","BK1587","BK1191","BK1588","01801","159938","BK1521","01177","09939","02315","BK1583","BK1515","06978","LU2488822045.USD","09688","02162","BK1161","LU2328871848.SGD","BK1574","BK1589","02257","02480"],"gpt_icon":0},{"id":"2492499929","title":"永泰生物-B盘中异动 早盘大幅跳水7.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492499929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492499929?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:37","pubTimestamp":1734485866,"startTime":"0","endTime":"0","summary":"2024年12月18日早盘09时37分，永泰生物-B股票出现波动，股价快速下跌7.53%。永泰生物-B股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，帝王国际投资、绿竹生物-B、思路迪医药股份涨幅较大，振幅较大的相关个股有晶泰控股-P、和誉-B、乐普生物-B，振幅分别为5.67%、4.67%、4.55%。永泰生物-B公司简介：永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121809374895ea3cd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121809374895ea3cd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2492785956","title":"万邦德：子公司WP103药品临床试验申请获得FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2492785956","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492785956?lang=zh_cn&edition=full","pubTime":"2024-12-17 20:20","pubTimestamp":1734438053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159992","BK0239","BK1583","BK0004","BK1161","06978","BK0028","002082","01477","BK1191","BK1576","HIE","BK1574","BK1141","03347","BK0050"],"gpt_icon":0},{"id":"2492932666","title":"石药集团再度交易临床初期创新药产品，业绩承压下或调整研发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932666","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492932666?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:27","pubTimestamp":1734431253,"startTime":"0","endTime":"0","summary":"仍需面对集采承压在今年第三季度，石药集团面临业绩下滑。石药集团前三季度成药业务收入同比下降3.5%，根据三季报中分析，成药业务收入下降主要受到集采和医保控费的影响。第十批药品国家集采中，石药集团有15款产品纳入，含石药集团欧意药业8个、石药集团中诺药业4个、石药银湖制药3个。预计随着多美素在国采中标降价后，石药集团的营收将受到进一步挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217183235a1f58bf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217183235a1f58bf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0008369823.USD","BK1521","LU1960683339.HKD","LU1226287875.USD","LU0140636845.USD","LU0326950275.SGD","BK1515","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1226288170.HKD","IE00B543WZ88.USD","LU1008478684.HKD","IE0008368742.USD","BK1161","IE00B031HY20.USD","LU1152091754.HKD","01093","LU1152091168.USD","BK1191","LU1226288253.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU1807302812.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","LU0067412154.USD","06978","LU1226287792.SGD","LU1226287529.USD","LU0501845795.SGD","LU0072913022.USD","LU1993786604.SGD","IE00BZ08YR35.GBP","BK1574"],"gpt_icon":0},{"id":"2492093736","title":"龙头3连击，国内眼药格局大洗牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2492093736","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492093736?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:20","pubTimestamp":1734430800,"startTime":"0","endTime":"0","summary":"上方“瞪羚社”即刻关注并加入社群      聚焦高成长公司，100000+投资菁英共同关注      国内创新含量最高的眼药企业之一开始展露锋芒。      远大医药（0512.HK）作为国内眼科创....","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OmFq1f7Mcl4trfglsRFLP2CxpZJXfiKSEW1nKX_dGehjEAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OmFq1f7Mcl4trfglsRFLP2CxpZJXfiKSEW1nKX_dGehjEAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241217A084CD00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241217A084CD00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2492930554","title":"创新药公司，大涨!","url":"https://stock-news.laohu8.com/highlight/detail?id=2492930554","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492930554?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:03","pubTimestamp":1734429780,"startTime":"0","endTime":"0","summary":"个股方面，乐普生物大涨受到市场关注；零售龙头滔搏虽面临挑战环境，股价仍然上扬。此外，乐普生物还宣布，其新药MRG003用于治疗复发性/转移性鼻咽癌的新药MRG003的上市申请已获国家药监局受理，并被纳入优先审评。政策和基本面层面，商保和医保支持力度加大，预计四季度医药板块将逐步进入反转周期，重点关注CXO及创新药领域的细分方向。零售龙头上涨受消费相关政策预期影响，滔搏股价持续反弹，12月17日涨幅达4.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656193632&idx=3&sn=e1adb170d4f56b1d257a3cfc79f4f2c9&chksm=8ad1296aeb7465665d392d0f31221d4be07e0b2b5cb32445977294eb83b01327aadd9a849652&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656193632&idx=3&sn=e1adb170d4f56b1d257a3cfc79f4f2c9&chksm=8ad1296aeb7465665d392d0f31221d4be07e0b2b5cb32445977294eb83b01327aadd9a849652&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06978","159992"],"gpt_icon":0},{"id":"2492498545","title":"【券商聚焦】国证国际：创新药企和医疗器械公司有望通过出海不断打开市场天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2492498545","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492498545?lang=zh_cn&edition=full","pubTime":"2024-12-17 14:20","pubTimestamp":1734416402,"startTime":"0","endTime":"0","summary":"对于医药板块， 在“医保+商保”模式不断推进、政策支持等因素驱动下，行业规模有望进一步扩大。由于中美定价差异大，企业可通过license out不断打开市场天花板。“医保+商保”模式打开健康险空间，创新药发展空间更大。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949796","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1181","LU1969619763.USD","159992","BK1161","02162","BK1515","01801","01177","BK1191","06978","159883","BK1222","BK1100","BK1589","BK1583","BK1521","LU2328871848.SGD","LU2488822045.USD","09996","09997","BK1587","06880","BK1574"],"gpt_icon":0},{"id":"2492099670","title":"中国创新药市场增长迅速，如何借力临床研发实现“新质”驱动？","url":"https://stock-news.laohu8.com/highlight/detail?id=2492099670","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492099670?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:56","pubTimestamp":1734400560,"startTime":"0","endTime":"0","summary":"　　2024年，大企业研发管线的比重逐年下滑，全球前二十大企业的研发管线占比已缩减至约12%。　　对于中国创新药市场而言，自“712”事件发生以来，我国临床创新领域经历了巨大的变革。　　另据最新数据，中国在全球医药研发中的贡献显著，其研发数目占全球的20.8%，仅次于美国。中国在研抗癌药物管线中，有821款处于不同临床开","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-12-17/doc-incztptx1876349.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-17/doc-incztptx1876349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2492767212","title":"逼近千亿市值，这家四川企业成为中国医药产业最大“黑马”","url":"https://stock-news.laohu8.com/highlight/detail?id=2492767212","media":"砺石商业评论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492767212?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:51","pubTimestamp":1734400282,"startTime":"0","endTime":"0","summary":"导语：市值逼近千亿大关的百利天恒，为中国创新药产品的未来发展指明了方向。      李平 | 作者 砺石商业评论 | 出品      1      一夜暴富的医药黑马      科创板上市两年市值增....","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OvZXHHwRDN-OVpGK0yuK7dsexmpfRphEeoaZSpLu7ItugAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OvZXHHwRDN-OVpGK0yuK7dsexmpfRphEeoaZSpLu7ItugAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241217A02GWP00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241217A02GWP00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BMS","BK1574","BK1161","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.2218},{"period":"1month","weight":0.3179},{"period":"3month","weight":-0.1524},{"period":"6month","weight":-0.2716},{"period":"1year","weight":-0.4314},{"period":"ytd","weight":-0.544}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.129933},{"month":2,"riseRate":0.5,"avgChangeRate":0.104699},{"month":3,"riseRate":0.25,"avgChangeRate":-0.117615},{"month":4,"riseRate":0.25,"avgChangeRate":-0.077145},{"month":5,"riseRate":0.5,"avgChangeRate":0.017788},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.121182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.037653},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026649},{"month":10,"riseRate":0.6,"avgChangeRate":0.001262},{"month":11,"riseRate":0.6,"avgChangeRate":0.007893},{"month":12,"riseRate":0.8,"avgChangeRate":0.085951}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}